In STEP-HFpEF, a prospective, randomized study of adults with HFpEF and obesity, weekly semaglutide weight-loss injections for 1 year led to substantial improvements in physical function and symptoms.
Semaglutide improves heart failure-related symptoms and physical function and results in greater weight loss compared with placebo in patients with he..
(CNN) — The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in